NF1 and cancer: The discovery that neurofibromin acts as a negative regulator of the RAS/MAPK signaling pathway explained how its loss leads to hyperactivation of this pathway [29], predisposing individuals to both benign and malignant tumors, and highlighted components of the pathway as promising therapeutic targets [30].